Abstract topics

1. Cervical cancer
2. Diagnostics
3. Endometrial cancer
4. Fertility/Pregnancy
5. Miscellaneous
6. Ovarian cancer
7. Palliative care
8. Pathology
9. Prevention of gynaecologic cancer
10. Quality of life after treatment
11. Translational research
12. Trophoblastic diseases
13. Vaginal and vulvar cancer
14. Organization of gynaecological cancer care

Participants of Patient advocacy seminar only:

15. Patient advocacy abstract

Instructions for authors of abstract

• Abstracts can only be submitted via the online form, abstracts submitted by fax or email will not be accepted.
• Abstracts must be submitted in English, using UK English spelling.
• The presenting author of an accepted abstract must register and attend the congress.
• The number of submissions is limited to 3 per presenting author.
• The number of authors is limited to 20 per abstract.
• Provide a short specific title indicating the scientific content of the abstract. The background and goals of the study should appear clearly to the reader. The methods need to outline patient group, methods applied, statistical considerations, if applicable. Results must contain data (except for Late Breaking abstracts [LBA]- see below), and the conclusion should be clearly expressed. The following structure will be required:
  • Introduction/Background*
  • Methodology
  • Results*
  • Conclusion*
  • Disclosures* (online recording via the submission form)
  • *mandatory fields
• The title may not exceed 150 characters. The abstract text may not be longer than 350 words (excluding title, authors and disclosures).
• All abbreviations must be defined the first time they appear in the text (but do not define in the title).
• Tables, charts and other graphics (maximum 2/abstract) are permitted and must be in high resolution JPG or JPEG format.
• Please submit short video preview file MP4, WMW, AVI, MPEG (up to 5 minutes long and maximally 500MB) for Video Presentation.
• Authors should indicate their presentation type preference:
  • Oral presentation preferred
  • Paper poster presentation (in-person part)
  • E-poster only
  • Video presentation
  • Oral presentation in the ENYGO young investigator session (only for authors up to 40 years)
  • Patient advocacy abstract (only for ENGAGe members)
  • Place holder for LBA

The Programme committee reserves the right to decide on the final allocation and presentation method.

• Disclosure of potential conflict of interest (e.g., grant support, consultancy, membership on advisory councils, speaker’s bureau) by all authors and source of funding are mandatory. Each listed author should prepare a one sentence statement that will be published with the abstract. All disclosures should be listed within the last 3 year (via online COI form).
• Abstracts submitted via commercial entities will be considered. However, these abstracts should report results from collaborative research conducted by independent (non-commercial) investigators. Investigators, as contributing authors who are employees of commercial entities will only be accepted if independent (academic, clinical and/or scientific) investigators are included as authors. The presenting author should not be an employee of the company.
• Systematic review/meta-analysis abstracts are acceptable.
• Trials in progress can be accepted as posters/e-posters but will not be accepted as oral presentations. These should not previously have been presented elsewhere.
• Encore abstracts (previously presented at a recent international meeting) can be accepted; however, they should be modified and include some new data if possible.
• If several abstracts are based on similar analyses of the same database and one of them is selected for oral presentation, the authors might be asked to combine some/all data into one presentation.
• Case reports for single cases will not be accepted unless they contain substantial translational work.
• Late Breaking Abstracts (LBA) are reserved for newly emerging data that is not available at the time of abstract submission. These could be for initial presentation of results, or significant secondary endpoint analyses. A placeholder LBA must be submitted containing the title, background, methods and type of results that will be presented. LBA will not be accepted at a later date unless a shell abstract has been submitted.